TwinStrand Biosciences Announces Leadership Transition
SEATTLE–TwinStrand Biosciences, Inc. (TwinStrand), the pioneer in Duplex Sequencing technology, which delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology, today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives. As part of this effort, TwinStrand has named Chad Brown as interim Chief Executive Officer, while TwinStrand founder, Jesse Salk, MD, PhD, will continue to serve the company as Chief Scientific Officer.
“I am pleased to welcome Chad to the TwinStrand team. His extensive experience building and expanding life science commercial organizations will be instrumental as we continue to grow the market for our unique clinical sequencing technology,” said Dr. Salk. “I am excited to return full-time to building our scientific and clinical groups and support Chad as we drive our business and commercial operations forward.”
TwinStrand raised $50 million in Series B funding May 6, 2021 and currently provides Duplex Sequencing assays for measurable residual disease (MRD) and mutagenesis via the company’s off-the-shelf and custom kit solutions.
“TwinStrand’s Duplex Sequencing is a truly transformative platform that has the potential to deliver significant clinical benefit. TwinStrand is making decisions today that better position the company to deliver on our mission of applying a powerful new genomic technology across disciplines to improve human health and accelerate scientific discovery,” said Mr. Brown. “This is a pivotal and exciting time for us. TwinStrand has already built numerous key partnerships and has seen much commercial success in the past years, and we are well positioned to build on this early progress. We are grateful for the contributions of everyone who has played a role in building TwinStrand to date and are looking forward to working with the extremely skilled and impassioned team to make the benefits of Duplex Sequencing accessible to everyone.”
About TwinStrand Biosciences
TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods. The company’s highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health, and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than two dozen peer-reviewed articles using Duplex Sequencing technology and have developed a portfolio of more than 150 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks, and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.twinstrandbio.com.